Biotechnology
Oncotelic Therapeutics Maintains $388M JV Valuation Amid Biotech Market Volatility
Oncotelic Therapeutics reported a stable $388 million fair value for its 45% stake in GMP Biotechnology, highlighting its partnership-driven model as a buffer against typical biotech cash burn pressures.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.
Sino Biological's Cell-Free Protein Synthesis Powers AI-Driven Protein Design Study Published in Nature Communications
Sino Biological's XPressMAX Cell-Free Protein Synthesis Kit enabled rapid experimental validation of AI-designed proteins in a study by Tencent AI for Life Sciences Lab, achieving over 100-fold activity improvements and thermostable enzymes.
Jupiter Neurosciences Raises $2 Million in Registered Direct Offering
Jupiter Neurosciences closes a $2 million registered direct offering to fund its clinical programs targeting CNS disorders and neuroinflammation.
Oncotelic Therapeutics Advances CNS Drug Delivery Strategy Amid BBB Breakthroughs
Oncotelic Therapeutics' $12.5M monetization of its CNS delivery system highlights growing industry focus on blood-brain barrier bypass technologies, unlocking new biotech market opportunities.
GeoVax CEO David Dodd to Discuss MVA-Based Vaccine Platforms for Broader Infectious Disease Preparedness in Tribe Public Webinar
GeoVax Labs CEO David Dodd will participate in a Tribe Public webinar on May 28, 2026, to discuss the need for platform-based vaccine technologies to address multiple viral threats like Ebola, Marburg, mpox, and hantavirus, emphasizing the limitations of single-threat preparedness.
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial evaluating TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurrence risk in a high-risk population.
VolitionRx Reports Progress in Diagnostics Pipeline, Including Feline Lymphoma Manuscript Submission Tied to $5M Milestone
VolitionRx provided a corporate update highlighting clinical and commercial progress, including a feline lymphoma manuscript submission linked to a $5 million milestone payment and licensing discussions with over a dozen global diagnostic companies.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with GelrinC
Regentis Biomaterials’ GelrinC offers a potential first-in-class, off-the-shelf solution for knee cartilage repair, with Phase III trial underway and CE Mark approval in Europe.
Helix BioPharma Grants Stock Options and Cancels Previous Grant Amid Pipeline Progress
Helix BioPharma Corp. announced the grant of 1,297,000 stock options to directors, officers, employees, and consultants, while canceling 2,200,000 options previously granted to a director, as the clinical-stage oncology company advances its pipeline including L-DOS47 and other candidates.
Regentis Biomaterials Advances GelrinC as Off-the-Shelf Solution for Knee Cartilage Repair, Targeting a 472,500-Procedure Gap
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could fill a market gap as no approved off-the-shelf regenerative solution exists in the U.S., with a pivotal FDA trial now over 50% enrolled and a new manufacturing process boosting yield by 400%.
GeoVax Highlights MVA Platform's Potential Amid Bundibugyo Ebola Outbreak
GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the need for flexible vaccine platforms like its MVA-based technology to address emerging viral threats.
Quantum BioPharma Hits Midpoint Enrollment in MS Imaging Study, Signaling Potential for Novel Diagnostic and Therapeutic Advances
Quantum BioPharma announced that its collaborative MS imaging study with Massachusetts General Hospital has reached midpoint enrollment, with preliminary PET tracer data showing promise for detecting active and gray matter lesions, which could accelerate development of its investigational MS therapy Lucid-MS.
Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer
Lantern Pharma announced FDA no objections to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, focusing on a specific EGFR mutation subgroup.
CEL-SCI Raises $7.2 Million in Public Offering to Advance Cancer Drug Multikine
CEL-SCI Corporation closed a $7.2 million public offering to fund continued development of its head and neck cancer treatment Multikine, highlighting the company's push to bring a novel immunotherapy to market.
Cardio Diagnostics Advances Personalized Heart Care Through AI and Epigenetics
Cardio Diagnostics Holdings is leveraging AI, epigenetics, and genetic insights to shift cardiovascular care from reactive treatment to predictive prevention, addressing heart disease as the leading cause of death worldwide.
GeoVax Raises $3 Million in Private Placement to Fund Vaccine Development
GeoVax Labs secures $3 million through a private placement with institutional investors to advance its mpox/smallpox vaccine and other pipeline programs.
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in three hours, supporting AI-powered high-throughput antibody drug discovery by eliminating traditional cell-based constraints.
Lantern Pharma Reports Q1 2026 Results: 47% R&D Cost Reduction and AI Platform Commercialization
Lantern Pharma's Q1 2026 results show a 47% year-over-year reduction in R&D spending, successful FDA milestones, and the launch of withZeta.ai, a commercial AI drug development platform that opens a new revenue stream and extends cash runway into 2027.
Cardio Diagnostics Merges Precision Medicine and AI to Tackle Global Cardiovascular Disease Burden
Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence and epigenetic biomarkers to deliver personalized cardiovascular risk assessments from a simple blood test, positioning itself at the forefront of precision medicine and preventive care.
SureNano Science's GEP-44 Could Disrupt the Obesity Drug Market with Improved Tolerability
SureNano Science Ltd. is advancing GEP-44, a next-generation GLP-1 therapy with a triple agonist mechanism, aiming to improve upon current obesity treatments by offering better tolerability and potential non-injectable delivery.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug
NanoViricides announced a $2 million registered direct offering with a single institutional investor, aiming to fund development of its broad-spectrum antiviral NV-387, which targets multiple viruses including COVID-19, influenza, and RSV.
Oncotelic Therapeutics Reports Q1 2026 Results, Highlights Progress in Oncology and AI Drug Development
Oncotelic Therapeutics reported first-quarter 2026 financial results and a corporate update, emphasizing advances in its oncology pipeline, AI-enabled drug development platform, and nose-to-brain CNS delivery system, while maintaining a $388 million valuation of its stake in GMP Biotechnology.
Oncotelic Therapeutics Highlights CNS Drug Delivery Innovation in NetworkNewsAudio Editorial
Oncotelic Therapeutics was featured in a NetworkNewsAudio editorial discussing the challenges of the blood-brain barrier and the company's N2B delivery system, with implications for biodefense and Alzheimer's treatment.
LIXTE Biotechnology Advances LB-100 Pipeline and Expands Proton Therapy Operations
LIXTE Biotechnology reports first-quarter progress with its lead cancer drug LB-100 moving into expanded ovarian cancer trials and growth at its Liora Technologies subsidiary, signaling strategic expansion in oncology.
Stonegate Initiates Coverage on StimCell Energetics, Highlighting eBalance Device Potential
Stonegate Capital Partners has initiated coverage on StimCell Energetics Inc., focusing on its single-product eBalance platform and the upcoming home-use redesign, with early data suggesting promise but requiring further validation.
GeoVax Advances GEO-MVA Phase 3 Trial as Mpox Vaccine Supply Concerns Persist
GeoVax reports first quarter 2026 financial results and details plans for a pivotal Phase 3 immunobridging study of its MVA-based mpox/smallpox vaccine, highlighting the strategic importance of diversifying orthopoxvirus vaccine supply amid global supply constraints.
SureNano Science Featured in BioMedWire Editorial Highlighting GLP-1 Innovation
SureNano Science Ltd. was featured in a BioMedWire editorial discussing its subsidiary GlucaPharm Inc. and its GEP-44 triple agonist peptide, which aims to improve obesity and diabetes treatment with better tolerability and potential non-injectable delivery.
SureNano Science Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
SureNano Science Ltd. and its subsidiary GlucaPharm Inc. are highlighted for developing GEP-44, a novel triple agonist peptide targeting the expanding GLP-1 market for obesity and metabolic disorders.
GeoVax Highlights Gedeptin's Role in Overcoming Immune Resistance in Cold Tumors
GeoVax Labs emphasizes its Gedeptin platform's potential to enhance checkpoint inhibitor efficacy by modulating the tumor microenvironment, positioning it as a key combination immunotherapy for immunologically cold tumors.